At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 152 enrolled
Drug / intervention
Fragmindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study
In Brief
A Phase 3 clinical trial evaluating Fragmin for Chronic Renal Failure. Completed, enrolled 152 participants across 19 sites.
Detailed Summary
The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Renal Failure
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartOct 2013
Primary CompletionMar 2016
TodayJul 2026
First PostedJun 18, 2013
Enrollment StartOct 1, 2013
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.0 years ago
Interventions
Fragmindrug
variable dosing regimen